Enveric Biosciences, Inc.

NasdaqCM ENVB

Enveric Biosciences, Inc. Free Cash Flow Yield on February 05, 2025

Enveric Biosciences, Inc. Free Cash Flow Yield is NA on February 05, 2025, a NA change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.
  • Enveric Biosciences, Inc. 52-week high Free Cash Flow Yield is NA on February 05, 2025, which is NA below the current Free Cash Flow Yield.
  • Enveric Biosciences, Inc. 52-week low Free Cash Flow Yield is NA on February 05, 2025, which is NA below the current Free Cash Flow Yield.
  • Enveric Biosciences, Inc. average Free Cash Flow Yield for the last 52 weeks is NA.
Key data
Date Free Cash Flow Yield Market Value Added (MVA) Price to Book Ratio (P/B) Price to Earnings Ratio (P/E)
Market news
SV Wall Street
NasdaqCM: ENVB

Enveric Biosciences, Inc.

CEO Dr. Joseph Edward Tucker Ph.D.
IPO Date May 4, 2015
Location United States
Headquarters 4851 Tamiami Trail North
Employees 7
Sector Healthcare
Industries
Pharmaceuticals Biotechnology Clinical Trials Cosmetics Drugstores & Retail Pharmacies Mental Health Personal Care Tobacco
Description

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Similar companies

ZURA

Zura Bio Limited

USD 1.78

4.09%

StockViz Staff

February 6, 2025

Any question? Send us an email